IE 11 is not supported. For an optimal experience visit our site on another browser.

PuraMed BioScience, Inc. Launches Direct Response Print Advertising Campaign

/ Source: GlobeNewswire

SCHOFIELD, Wis., Sept. 14, 2010 (GLOBE NEWSWIRE) -- PuraMed BioScience, Inc. (OTCBB:PMBS) announced today that it is launching a print advertising campaign for its migraine medication LipiGesic™ M. The first ads will appear in USA Weekend Magazine during the weekend of Sept. 18-19. USA Weekend Magazine is an insert publication in the weekend editions of daily newspapers across the country.

Advertisements featuring LipiGesic™ M will be published in the edition printed for the Midwest region, reaching over 7.9 million households. The Midwest region includes Iowa, Kansas, Minnesota, Missouri, Nebraska and South Dakota. USA Weekend Magazine in this region is included in approximately 40 newspapers.

Two LipiGesic™ M advertisements will be featured in the Sept. 18-19 issue. The first is a traditional print advertisement and the second is an "advertorial"—an advertisement in the form of a written article. Both advertisements are "direct response", which means they encourage readers to call in or log on to purchase LipiGesic™ M after reading the ad.

"We look forward to our first two print advertisements appearing in USA Weekend Magazine," said PuraMed BioScience CEO Russell Mitchell. "With these advertisements, nearly 8 million households now have the opportunity to learn about LipiGesic™ M and its benefits. By adding a print campaign into our marketing and advertising mix, we are continuing our strategy to introduce LipiGesic™ M to a broad audience before our national retail launch."

While announcing new advertising campaigns, the Company is continuing to meet with national retail chains in order to prepare for the retail launch of LipiGesic™ M by the end of the calendar year. PuraMed also anticipates the potential publication of the results of a clinical study of LipiGesic™ M, which can generate significant awareness and increase visibility of the product to both the medical community and the general public.

About the PuraMed BioScience, Inc.:

PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches, the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for common tension headaches. For more information on PuraMed, visit the Company website at , join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at .

Forward Looking Statements:

This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

CONTACT: PuraMed BioScience, Inc. Russell Mitchell, Chairman and CEO 715-359-6373 Investor Awareness, Inc. Investor Relations: Tony Schor James Foy 847-945-2222 North Shore Public Relations, Inc. Media Contact: Renae Placinski 847-945-4505